Scalper1 News
Specialty-drug giant Valeant Pharmaceuticals International (VRX) agreed to drop its litigation against hostile-takeover target Allergan in exchange for Allergan allowing the originally scheduled Dec. 18 special shareholder meeting that could speed the potential merger. But while the meeting go-ahead makes a merger likelier, BMO Capital Markets analyst David Maris reported after a visit with Allergan (AGN) executives that they still sounded Scalper1 News
Scalper1 News